[Ranibizumab tachyphylaxis in a case of macular edema related to central retinal vein occlusion: Lasting effectiveness of switching to aflibercept].
Clinique Pasteur, Ophtasiam, 5, bis rue Amiral-Linois, 29200 Brest, France; Clinique Pasteur, Lanroze, rue Auguste-Kervern, 29200 Brest, France. Electronic address: joel.gambrelle@hotmail.fr.
J
J
Gambrelle
Clinique Pasteur, Ophtasiam, 5, bis rue Amiral-Linois, 29200 Brest, France; Clinique Pasteur, Lanroze, rue Auguste-Kervern, 29200 Brest, France.
A
A
Robinet
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012170:Retinal Vein Occlusion / Q000150:complications; D013618:Tachyphylaxis; D013997:Time Factors; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab